Antiviral Agents for the Prevention and Treatment of Herpes Simplex Virus Type-1 Infection in Clinical Oncology: A Network Meta-Analysis

Farah Wasim Aribi Al-Zoobaee 1, Loo Yee Shen 2, Sajesh K. Veettil 3, Divya Gopinath 4, Mari Kannan Maharajan 2 and Rohit Kunnath Menon 1,5*,

1 Department of Pharmacy Practice, School of Pharmacy, International Medical University, Kuala Lumpur 57000, Malaysia; FARAH.WASIM@student.imu.edu.my
2 School of Pharmacy, International Medical University, Kuala Lumpur 57000, Malaysia; loo.yeeshen@student.imu.edu.my (L.Y.S); MariKannan@imu.edu.my (M.K.M.)
3 Department of Pharmacotherapy, College of Pharmacy, University of Utah, Salt Lake City, UT 84132, USA; sajesh.vijay@gmail.com
4 Oral Diagnostics and Surgical Sciences, School of Dentistry, International Medical University, Kuala Lumpur 57000, Malaysia; DivyaGopinath@imu.edu.my
5 Division of Clinical Dentistry, School of Dentistry, International Medical University, Kuala Lumpur 57000, Malaysia
* Correspondence: rohitkunnath@imu.edu.my

Received: 24 October 2020; Accepted: 13 November 2020; Published: 30 November 2020

Abstract: Cancer therapy may be complicated and compromised by viral infections, including oral herpes simplex virus (HSV) infection. This network meta-analysis aimed to identify the best antiviral agent to prevent or treat oral HSV infection in patients being treated for cancer. A search was conducted for trials published since inception until the 10th of May 2020 in MEDLINE, EMBASE and the Cochrane Central Register of Controlled Trials. A network meta-analysis was performed on the data from randomized controlled trials that assessed antiviral agents for preventive or therapeutic activity vs. placebo, no treatment or any other active intervention in patients being treated for cancer. The agents were ranked according to their effectiveness in the prevention of oral HSV using surface under the cumulative ranking (SUCRA). Grading of Recommendations, Assessment, Development and Evaluations (GRADE) was used to assess the certainty of the evidence. In total, 16 articles were included. The pooled relative risk (RR) to develop oral HSV infection in the acyclovir group was 0.17 (95% CI: 0.10, 0.30), compared to 0.22 (95% CI: 0.06, 0.77) in the valacyclovir group. Acyclovir ranked highest for the prevention of oral HSV followed by valacyclovir. Subgroup analysis with different acyclovir regimens revealed that the best regimens in terms of HSV-1 prevention were 750 mg/m² acyclovir administered intravenously followed by 1600 mg per day orally. Acyclovir (250 mg/m² per day) administered intravenously was the least effective against the prevention of oral HSV.

Keywords: herpes simplex virus; cancer; antiviral; prophylaxis; systematic review; network meta-analysis

1. Introduction

Cancers are currently the second major cause of death worldwide after cardiovascular disease [1]. Treatment of cancer is usually associated with many complications that may generate additional burden affecting the patient’s quality of life and could cause pain, difficulty in swallowing, mucositis, salivary gland dysfunction, malnutrition, anemia, weight loss, and can potentially cause sepsis leading to life-threatening systemic infections [2]. Oral mucositis is one of the most common and
troublesome adverse effect of many therapeutic strategies of cancer (chemotherapy, radiotherapy, and chemo-radiotherapy), which can produce pain, ulceration, malnutrition, and may impact the treatment as well [3]. Impact on the treatment regimen can be considered as a serious adverse effect which may be the consequence of an oral infection. Oral infections could be attributed to bacterial, fungal, or viral infections, which are leading causes of morbidity and mortality in patients undergoing cancer treatment.

Herpes Simplex Virus (HSV) is a very common viral infection and the majority of the people are usually infected early in their life. The prevalence of HSV differs according to age, socioeconomic status, and geographic location [4–6].

HSV can cause several types of diseases, ranging from labialis and stomatitis to blinding keratitis and, rarely, encephalitis. The clinical symptoms accompanying oral HSV ranges from asymptomatic infection to life-threatening diseases. Gingival stomatitis and pharyngitis are the most common manifestations of the first episode. Symptoms such as fever, chills, fatigue, muscle aches, and blisters on or around the lips and within the mouth will be experienced by the patient and will last for 10–14 days. The incubation period of HSV-1 ranges from 1 to 26 days, with a median range of 6 to 8 days [7–9]. After the primary infection, the virus tends to reside in the trigeminal ganglia; this persistent form is known as a latent infection. However, HSV-1 can episodically reactivate from latency, and it is estimated that one-fourth of people who have seropositive HSV test will develop oral HSV reactivation once or four times per year [9–11]. Recurrence mainly occurs after the virus gets triggered by a stimulus [12]. Triggers include sunlight, menstruation, stress, trauma, febrile illness, chemotherapy, radiotherapy, or immunosuppression [13,14]. Dreizen et al. [15], reported that in 1000 patients receiving cancer treatment, 9.7% of them were diagnosed with an oral infection, and of these, 10.7% were due to viruses. In previous studies, the prevalence of oral infection in immunocompromised participants is under-reported, and up to 40–50% of these patients were reported to be diagnosed with herpetic infections [16–18]. Oral HSV infection is known to be more aggressive in patients being treated for cancer when compared to immunocompetent individuals. Reactivated HSV-1 infections develop as large intraoral ulcers or extensive necrotic lesions around the mouth. HSV-1 esophagitis rarely develops in immunocompetent subjects; however, it is usually seen in immunocompromised individuals. Up to 80% of seropositive HSV patients receiving allogeneic stem cell transplants have been reported to develop HSV-1 reactivation episodes [19]. More than 60% of patients with acute leukemia receiving chemotherapy have been previously reported to develop HSV-1 reactivation [20–23]. Antiviral prophylaxis has been recommended for HSV-seropositive patients with leukemia as per the guidelines of the Second European Conference on infections in leukemia [24]. Further, several guidelines have recommended antiviral prophylaxis for patients undergoing haematopoietic stem cell transplantation against HSV-1 [25–27].

Owing to this morbidity, there has been much effort in developing antiviral agents to treat and prevent oral HSV in patients undergoing cancer treatment. The main aims of antiviral drugs for HSV encompass hindrance of HSV reactivation, pain reduction, reducing the duration of viral shedding and symptoms [28]. Several types of antiviral agents such as acyclovir, famciclovir, penciclovir, and valacyclovir have been recommended for the treatment and/or prevention of HSV-1 [29]. All these agents are available as oral dosage forms, but only acyclovir is available as a parenteral and topical formulation. Acyclovir requires more frequent dosing due to its poor bioavailability which is estimated to be only 20%, and its plasma half-life which is approximately 3 h [30]. At the same time, valacyclovir and famciclovir have good oral bioavailability, thus requiring less frequent dosing. All drugs used for the treatment or prevention of HSV have a wide safety margin because they will be activated by the viral thymidine kinase only inside the infected cells [31].

Evidence regarding the effectiveness of antiviral agents in the prevention or treatment of oral HSV in patients undergoing cancer treatment is still inconclusive. Hence, this systematic review and meta-analysis aimed to enhance the understanding of the oral HSV infection burden and complications
in patients receiving cancer regimens and highlights the importance of using the most effective and safe antiviral agent to treat and prevent oral HSV infection.

2. Materials and Methods

2.1. Search Strategy

This systematic review and network meta-analysis (NMA) was conducted based on the general principles outlined in the Cochrane Handbook for Systematic Reviews of Interventions, and it was reported based on the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) extension statement for network meta-analysis [32,33]. An inclusive search of randomized controlled trials published from inception until the 10th of May 2020 was conducted in Medline, Cochrane Central Register of Controlled Trials and Embase. The search strategies and search terms used in Embase, Medline, and Cochrane Central Register of Controlled Trials are documented in Table A1. in Appendix A. The search was restricted to publications in the English language and human studies. For additional studies, references of previously published reviews were scanned.

Selection criteria based on the Participants (Ps), Intervention (I), Comparisons (Cs) and Outcomes (Os) statements are given below:

- **Participants**: Patients undergoing cancer treatment. Adults, children, or both were included in the search.
- **Intervention**: Any antiviral agent used for the prevention or treatment of oral herpes simplex virus infection were included.
- **Comparisons**: Active intervention, placebo, or no treatment.
- **Outcomes**: The primary outcome analyzed for prevention was the occurrence or absence of herpes simplex virus infections, clinically or as a positive culture. The primary outcome analyzed for treatment was the time required for complete healing of the lesions. Secondary outcomes were recurrence of lesions, the time required for pain relief, duration of viral shedding, and adverse effects.

2.2. Data Extraction and Management

Titles and abstracts of citations from the electronic databases were screened for relevant articles and the full-text of all potentially relevant articles were extracted. The inclusion and exclusion criteria were applied for all potentially eligible articles. When studies had duplicate publications with the same data, the most recent relevant data from these publications were included in the review and analysis. Two reviewers conducted the screening and selection process and a consensus was obtained; in case of any disagreement, a third reviewer was consulted. The extraction form was created following the Cochrane Handbook for Systematic Reviews of Interventions guidelines by consensus amongst all the reviewers. The data from randomized controlled trials (RCTs) were extracted and separated into the following sections: study characteristics, population characteristics, intervention characteristics, and outcome definitions and measures. For all outcomes, the initial number of participants randomized to each trial arm was used. We performed the analyses irrespective of how the authors of the original trials had analyzed the data (intention-to-treat principle) [34].

2.3. Quality of Assessment

Cochrane risk of bias tool 2.0 was used to evaluate the risk of bias of each study [35].

2.4. Strategy for Data Synthesis

Data were analyzed based on the intention-to-treat principle. Risk ratios and 95% confidence intervals were used as summary statistics in this network meta-analysis. A standard pairwise meta-analysis was performed by using a random-effects (DerSimonian and Laird) model for direct comparisons [32]. If a direct comparison was based on two or more studies, heterogeneity between
the trials was evaluated by considering the I² statistics; an I² estimate ≥50% was interpreted as evidence of substantial levels of heterogeneity [32]. A random-effects network meta-analysis was applied to synthesize the available evidence by combining direct and indirect evidence from different studies [36,37]. Network inconsistency, which refers to a disagreement between direct and indirect estimates, was assessed using a global inconsistency test by fitting a design-by-treatment model. A network plot was used to map different interventions and placebo.

3. Results
3.1. Study Selection

The search yielded 2315 potentially relevant publications (151 Central, 1680 Embase, and 484 Medline). A total of 432 articles were eliminated due to duplication, following which 1883 articles underwent screening based on the title and abstract. A total of 51 full-text articles were reviewed and three articles which presented the same data were eliminated due to multiple publications [38–40]. Eventually, 19 randomized controlled trials [20,41–58] which met the inclusion criteria were included in the qualitative review and 16 [20,41–55] articles were included in the meta-analysis. Figure 1 depicts the trial selection flow chart.

![Figure 1. Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flow diagram summarizing the study selection process for eligible trials.](image-url)
3.2. Study Characteristics

Table 1 shows the characteristics of the included RCTs. Trials included were published from 1981 to 2002. The drugs assessed included acyclovir in oral and intravenous (IV) dosage forms and valacyclovir. Among the 19 trials, a total of 16 studies with 949 participants comparing three interventions were included in the NMA for the efficacy of antifungal agent in preventing oral HSV infection in patients undergoing cancer treatment (Figure 2) [20,41–55]. These included 14 trials comparing acyclovir with placebo [20,41–53] while another two trials compared valacyclovir and acyclovir [54,55]. The study by Orlowski (2004) was excluded from this analysis because the study was comparing two different valacyclovir doses (500 vs. 1000 mg) and hence cannot be connected to the network loop [56]. For the treatment outcome, only two trials assessed acyclovir activity [57,58] whereas none of the available trials evaluated the efficacy of valacyclovir.

**Figure 2.** Network plot of herpes simplex virus incidence by drug class. Notes: The size of the node and the thickness of the straight line are proportional to the number of trials and the presence of direct evidence between compared agents. Abbreviations: PBO, placebo; ACY, acyclovir; VAL, valacyclovir.
Table 1. Characteristics of included randomized controlled trials (RCTs). Abbreviations: ACY, acyclovir; VAL, valacyclovir; PBO, placebo; O, oral; IV, intravenous.

| Author (Year)          | Country | Study Design                          | Study Comparison | Antiviral: Dose and Duration                                                                 | Sample Size | Dropout Rate | Outcome: Oral HSV Infection | Duration of Treatment |
|------------------------|---------|---------------------------------------|------------------|---------------------------------------------------------------------------------------------|-------------|--------------|-----------------------------|----------------------|
| SARAL et al., 1983     | US, Maryland | randomized, double-blind, placebo controlled | ACY vs. PBO     | IV ACY 250 mg/m² body surface area, three times daily                                      | 30          | 3%           | ACY: 0/15 PBO: 11/15         | 32 days or until discharged from the hospital or until a culture-positive herpes simplex virus infection was found |
| Henn et al., 1983      | London  | randomized, double-blind               | ACY vs. PBO     | IV ACY, 5 mg/kg, twice daily                                                               | 60          | 1.6%         | ACY: 2/29 PBO: 15/30         | 14 months            |
| Bergmann et al., 1997  | Denmark | randomized, double-blind, placebo controlled | ACY vs. PBO     | O-ACY 400 mg, twice daily                                                                  | 90          | 0%           | ACY: 1/45 PBO: 8/45          | 28 days              |
| G Lundgren et al., 1985 | Sweden | randomized, double-blind and placebo controlled | ACY vs. PBO     | IV ACY at a dose of 250 mg/m², twice daily                                                  | 42          | 0%           | ACY: 1/20 PBO: 6/22          | 6 months             |
| Saral et al., 1981     | US      | double-blind                           | ACY vs. PBO     | IV 250 mg/m² acyclovir, every eight hours                                                   | 20          | 0%           | ACY: 0/10 PBO: 7/10          | 18 days              |
| Bubley et al., 1989    | US      | randomized, double-blind               | ACY vs. PBO     | O-ACY as four 200-mg capsules, twice daily                                                  | 57          | 17.5%        | ACY: 3/27 PBO: 5/30          | 7 weeks              |
| Shepp et al., 1985     | US      | randomized, double-blind               | ACY vs. PBO     | IV ACY 250 mg/m², once daily                                                               | 30          | 10%          | ACY: 6/14 PBO: 9/13          | 4 weeks              |
| Lonnqvist et al., 1993 | Sweden  | double-blind                           | ACY vs. PBO     | O-ACY 200 mg, four times daily                                                             | 116         | 7.7%         | ACY: 0/52 PBO: 15/55         | Duration varied      |
| WADE et al., 1984      | US      | double-blind                           | ACY vs. PBO     | O-ACY 400 mg, every four hours                                                             | 49          | 0%           | ACY: 5/24 PBO: 17/25         | 35 days              |
| Gluckman et al., 1983  | France  | double-blind                           | ACY vs. PBO     | O-ACY 200 mg, every six hours                                                             | 40          | 2.5%         | ACY: 0/20 PBO: 13/20         | from day 8 to day 35 after transplant |
| Anderson et al., 1984  | UK      | double-blind                           | ACY vs. PBO     | O-ACY 200 mg four times daily                                                              | 41          | 2.5%         | ACY: 1/20 PBO: 12/20         | 6 weeks              |
| Liesveld et al., 2002  | US      | randomized open label                  | VAL vs. ACY     | O-VAL 1 g, twice daily; IV-ACY 250 mg/m², twice daily                                      | 30          | 3.3%         | VAL: 0/14 ACY: 3/16          | until the day of engraftment |
| Prentice et al., 1983  | London  | randomized placebo-controlled          | ACY vs. PBO     | IV-ACY 5 mg/kg infused over one hour, once daily                                           | 60          | 1.6%         | ACY: 2/29 PBO: 15/30         | during the period of neutropenia |
| Shepp et al., 1987     | US      | double-blind                           | ACY vs. PBO     | O-ACY 800 mg, twice daily                                                                  | 51          | 31%          | ACY: 7/25 PBO: 12/26         | from day 31 till 75 days     |
| Selby et al., 1989     | UK      | double-blind                           | ACY vs. PBO     | IV acyclovir 5 mg kg three times daily. Children less than 12 years received 250 mg/m², followed by 400 mg orally 6-hourly | 82          | 0%           | ACY: 9/42 PBO: 12/40         | Over one year         |
Table 1. Cont.

| Author (Year)          | Country | Study Design                          | Study Comparison     | Antiviral: Dose and Duration | Sample Size | Dropout Rate | Outcome: Oral HSV Infection | Duration of Treatment |
|------------------------|---------|---------------------------------------|----------------------|-----------------------------|-------------|--------------|-----------------------------|-----------------------|
| Warkentin et al., 2002 [55] | Canada  | single-blind, randomized, 3-group clinical trial | VAL 500 vs. VAL 250 vs. ACY 400 | O-VAL (500 mg twice daily); O-VAL (250 mg twice daily); O-ACY (400 mg thrice daily) | 151         | 0%           | VAL 500 mg: 8/48             | Duration varied       |
| Orlowski et al. [56]   | Sidney  | randomized open label                 | VAL 500 vs. VAL 1000  | Every 8 h                   | 81          | 14.8%        | VAL 500 mg: 0/40             | 1979 days             |
| Wade et al., 1982 [57] | US      | randomized, double-blind              | IV-ACY 750 mg/m² body surface area once daily | 31             | 0%          | ACY:15/17                  | 7 days                |
| Shepp et al., 1985 [58] | -       | randomized, double-blinded, placebo-controlled | ACY vs. PBO         | O-ACY 400 mg five times daily | 21          | 0%           | -                           | 10 days               |
Quality of RCTs

Quality assessment of each study using the Risk of Bias (ROB) assessment tool is provided in Table 2. Among the RCTs, 10 trials were evaluated and found to have a high ROB, whereas the remaining studies were at low or some concern ROB.

Table 2. Risk of bias assessment of included RCTs in network-meta analysis.

| Author   | Year | Random Sequence Generation | Allocation Concealment | Blinding of Participants and Personnel | Blinding of Outcome Assessment | Incomplete Outcome Data | Selective Reporting | Overall Bias          |
|----------|------|-----------------------------|------------------------|----------------------------------------|-------------------------------|------------------------|---------------------|----------------------|
| Saral    | 1983 | +                           | ?                      | +                                      | +                             | ?                      | Low risk            |                     |
| Hans     | 1983 | +                           | ?                      | +                                      | +                             | ?                      | ?                   |                     |
| Bergmann | 1997 | +                           | ?                      | +                                      | +                             | +                      | Low risk            |                     |
| O’Lundgren | 1985 | ?                            | +                      | +                                      | +                             | ?                      | ?                   |                     |
| Rubley   | 1989 | +                           | +                      | +                                      | +                             | +                      | ?                   |                     |
| Wade     | 1984 | ?                            | ?                      | +                                      | +                             | +                      | ?                   |                     |
| Anderson | 1984 | ?                            | ?                      | +                                      | +                             | +                      | ?                   |                     |
| Shepp    | 1987 | +                           | ?                      | +                                      | +                             | ?                      | ?                   |                     |
| Liesveld | 2002 | +                           | ?                      | +                                      | +                             | ?                      | ?                   |                     |
| Selby    | 1989 | +                           | +                      | +                                      | +                             | +                      | ?                   |                     |
| Warkentin | 2002 | ?                            | ?                      | +                                      | +                             | ?                      | ?                   |                     |
| Saral    | 1981 | +                           | ?                      | +                                      | +                             | +                      | ?                   |                     |
| Shepp    | 1985 | +                           | ?                      | +                                      | +                             | +                      | ?                   |                     |
| Lorenzo | 1993 | +                           | ?                      | +                                      | +                             | +                      | ?                   |                     |
| Prentice | 1983 | ?                            | ?                      | +                                      | +                             | ?                      | ?                   |                     |
| Gluckman | 1983 | +                           | ?                      | +                                      | +                             | ?                      | ?                   |                     |

Based on the NMA results, acyclovir (RR, 0.17 (95% CI: 0.10, 0.30)) and valacyclovir (RR, 0.22 (95% CI: 0.06, 0.77)) significantly reduce the risk of developing oral HSV infection when compared to placebo. No significant difference was observed for the comparison on efficacy between acyclovir and valacyclovir in the prevention of oral HSV (RR, 0.79, (95% CI: 0.25, 2.48)) (Table 3).

Table 3. Comparative efficacy of valacyclovir and acyclovir in the prevention of oral herpes simplex virus (HSV) infection in patients receiving cancer treatment through network meta-analysis. Abbreviations: ACY, acyclovir; VAL, valacyclovir; PBO, placebo. Note: Pairwise (upper right portion) and network (lower left portion) meta-analytic results. Outcomes are expressed as risk ratio (95% confidence intervals). For the pairwise meta-analyses, a relative risk of less than 1 indicates that the treatment specified in the row is more efficient. For the network meta-analysis, a relative risk of less than 1 shows that the treatment specified in the column is more efficient. Bold and shaded results indicate statistical significance.

|        | ACY | VAL | PBO |
|--------|-----|-----|-----|
| RR     | 0.79 | 0.22 | 0.18 |
| CI     | (0.27, 2.27) | (0.12, 0.27) | NA |

Surface under the cumulative ranking (SUCRA) ranks and curves for efficacy outcomes are presented in Table 4 and Figure 3. Acyclovir was ranked the best in preventing oral HSV infection (SUCRA score—0.83), followed by valacyclovir (SUCRA score—0.66) and placebo.
Table 4. Results of network meta-analysis: Incidence of herpes simplex virus, with surface under the cumulative ranking (SUCRA) ranking. Abbreviations: ACY, acyclovir; VAL, valacyclovir; PBO, placebo.

| Intervention | Incidence of Herpes Simplex Virus | SUCRA Rank (Score) |
|--------------|-----------------------------------|--------------------|
| ACY          | 0.17 (0.10, 0.30)                 | 1 (0.83)           |
| VAL          | 0.22 (0.06, 0.77)                 | 2 (0.66)           |
| PBO          | Reference                         | 3 (0.005)          |

Overall inconsistency
Chi-square (p value) 1.87 (0.60)
Number of studies 16

Figure 3. SUCRA ranking curve of antiviral agents for the prevention of oral herpes simplex virus infection. Abbreviations: ACY, acyclovir; VAL, valacyclovir; PBO, placebo.

According to the pairwise meta-analysis (Figure 4), acyclovir causes a significant reduction in the risk of oral HSV when compared to placebo (RR, 0.18 (95% CI: 0.12, 0.27)). No significant difference was observed for the comparisons between valacyclovir and acyclovir (RR, 1.26 (95% CI: 0.44, 3.67)). Heterogeneity was low for the included studies between acyclovir vs. placebo and valacyclovir.
Subgroup analysis: comparison of the total daily dose of acyclovir and dosage forms in the prevention of oral HSV incidence.

A total of 13 trials comparing eight interventions were included in the subgroup analysis to assess the efficacy of different acyclovir doses in the prevention of oral HSV incidence in patients undergoing cancer treatment (Figure 5) [20,41–50,52,53]. The study by Selby (1989) [51] was eliminated from the analysis since the study included both children and adults in the treatment group with two different doses—the total daily dose for adults was 3200 mg oral acyclovir, whereas 1600 mg oral acyclovir was given to children. However, the overall result of this study mixed children and adults together.

Figure 4. Forest plot of pairwise meta-analysis analyzing the antiviral prophylaxis efficacy against oral HSV. Note: 1, Saral-1981; 2, Gluckman-1983; 3, Hann-1983; 4, Prentice-1983; 5, Saral-1983; 6, Anderson-1984; 7, Wade-1984; 8, Lundgren-1985; 9, Shepp-1985; 10, Shepp-1987; 11, Bubley-1989; 12, Selby-1989; 13, Lonnqvist-1993; 14, Bergmann-1995; 15, Liesveld-2002; 16, Warkentin-2002.

Figure 5. Network plot: incidence of herpes simplex virus with different acyclovir regimens. Abbreviations: PBO, placebo; O-ACY, oral acyclovir; IV-ACY, intravenous acyclovir.
Pairwise meta-analysis was conducted for the seven different acyclovir regimens based on dosing (Figure 6). Most acyclovir regimens were significantly better than placebo at preventing oral HSV infection except for intravenous acyclovir at 500 and 250 mg/m². Compared to placebo, oral acyclovir at 800 mg per day (RR, 0.07 (95% CI: 0.02–0.22)), oral acyclovir at 1600 mg per day (RR, 0.06 (95% CI: 0.01–0.45)), intravenous acyclovir at 10 mg/kg per day (RR, 0.14 (95% CI: 0.05–0.37)), intravenous acyclovir at 750 mg/m² (RR, 0.06 (95% CI: 0.01–0.39)) and oral acyclovir at 2000 mg (RR, 0.18 (95% CI: 0.06–0.55)) significantly reduced the incidence of oral HSV infection. Overall, the statistical heterogeneity was low (I² = 0.0%).

![Figure 6. Forest plot of pairwise meta-analysis for studies assessing the efficacy of different acyclovir regimens in preventing oral HSV in patients being treated for cancer.](https://example.com/figure6.png)

Based on the NMA (Table 5), compared to placebo, all the examined dose were statistically significant in terms of reducing the incidence of oral HSV infection except for the intravenous doses of 500 and 250 mg/m². Intravenous acyclovir (750 mg/m²) (RR, 0.06 (95% CI: 0.01, 0.39)) and intravenous acyclovir (10 mg/kg) (RR, 0.14 (95% CI: 0.05, 0.37)) significantly reduced the risk of oral HSV. Among oral acyclovir, the total daily dose of 800 (RR, 0.07 (95% CI: 0.02, 0.22)), 1600 (RR, 0.06 (95% CI: 0.01, 0.45)) and 2000 mg (RR, 0.18 (95% CI: 0.06, 0.55)) was associated with a significant reduction in the incidence of oral HSV infection.
Table 5. Comparative efficacy of different acyclovir doses in the prevention of oral HSV infection in patients receiving cancer treatment.

| Dosage Form | Dose | Placebo | NA | NA | NA | NA | 0.14 (0.05, 0.37) |
|-------------|------|---------|----|----|----|----|-----------------|
| IV-ACY10 MG/KG | 0.33 (0.09, 1.27) | 1.88 (0.20, 17.79) | NA | NA | NA | NA | 0.41 (0.17, 1.02) |
| IV-ACY250 MG/M2 | 0.63 (0.06, 6.13) | 7.42 (0.87, 62.95) | 3.96 (0.23, 66.89) | IV-ACY750 MG/M2 | NA | NA | NA | 0.22 (0.03, 1.73) |
| IV-ACY500 MG/M2 | 2.25 (0.25, 20.58) | 6.72 (0.76, 59.63) | 3.58 (0.20, 62.69) | IV-ACY1600 | NA | NA | NA | 0.06 (0.01, 0.39) |
| IV-ACY750 MG/M2 | 0.75 (0.17, 3.25) | 2.25 (0.54, 9.27) | 1.20 (0.12, 12.52) | O-ACY1600 | NA | NA | NA | 0.06 (0.01, 0.45) |
| O-ACY1600 | 1.95 (0.43, 8.76) | 5.82 (1.36, 25.01) | 3.10 (0.29, 32.72) | O-ACY800 | NA | NA | NA | 0.18 (0.06, 0.55) |
| O-ACY2000 | 0.14 (0.05, 0.37) | 0.41 (0.17, 1.02) | 0.22 (0.03, 1.73) | O-ACY800 | 0.06 (0.01, 0.39) | 0.07 (0.02, 0.22) |

When comparing the efficacy between different total daily doses and dosage forms of acyclovir, there was no significant reduction observed in the incidence of oral HSV infections (Table 5). SUCRA ranks and curves for the efficacy of different acyclovir regimens in the prevention of oral HSV infection in patients receiving cancer treatment are provided in Table 6 and Figure 7. Among the interventions, 750 mg/m² intravenous acyclovir (SUCRA score—0.79) was ranked the best in the prophylaxis of oral HSV infection, followed by 1600 mg oral acyclovir (SUCRA score—0.77), 800 mg oral acyclovir (SUCRA score—0.76), 10 mg/kg intravenous acyclovir (SUCRA score—0.56) and 2000 mg oral acyclovir (SUCRA score—0.46).

Figure 7. SUCRA ranking curve of different acyclovir regimens. Abbreviations: PBO, placebo; O-ACY, oral acyclovir; IV-ACY, intravenous acyclovir. Network consistency and small study effects. No inconsistency was observed for any outcome in the network meta-analysis (NMA). (Table 7).
**Table 6.** Incidence of herpes simplex virus with different acyclovir regimens and SUCRA ranking. Abbreviations: PBO, placebo; O-ACY, oral acyclovir; IV-ACY, intravenous acyclovir.

| Intervention          | Incidence of Herpes Simplex Virus | RR (95% CI) | SUCRA Rank (Score) |
|-----------------------|-----------------------------------|-------------|---------------------|
| IV-ACY 750MG/M2       | 0.06 (0.01, 0.39)                 | 1 (0.79)    |
| O-ACY 1600            | 0.06 (0.01, 0.45)                 | 2 (0.77)    |
| O-ACY 800             | 0.07 (0.02, 0.22)                 | 3 (0.76)    |
| IV-ACY 10MG/KG        | 0.14 (0.05, 0.37)                 | 4 (0.56)    |
| O-ACY 2000            | 0.18 (0.06, 0.55)                 | 5 (0.46)    |
| IV-ACY 500MG/M2       | 0.22 (0.03, 1.73)                 | 6 (0.42)    |
| IV-ACY 250MG/M2       | 0.41 (0.17, 1.02)                 | 7 (0.22)    |
| PBO reference         |                                   | 8 (0.02)    |
| Overall inconsistency  | Inconsistency model requested, but there is no source of inconsistency. No tests were performed. |
| Chi-square (p value)  |                                   |             |
| Number of studies     | 13                                |

**Table 7.** Assessment of global inconsistency for risk of incidence of oral HSV in networks using “design-by-treatment” interaction model.

| Network Outcome                        | Chi Square | p Value for Test of Global Inconsistency |
|----------------------------------------|------------|----------------------------------------|
| Incidence of oral HSV by drug class    | 1.87       | 0.60                                   |
| Incidence of oral HSV by dosage form and total daily dose | - | - |

Pairwise (upper right portion) and network (lower left portion) meta-analytic results. Outcomes are expressed as risk ratios (95% confidence intervals). For the pairwise meta-analyses, a relative risk less than 1 indicates that the treatment specified in the row is more efficacious. For the network meta-analysis, a relative risk less than 1 indicates that the treatment specified in the column is more efficacious. Bold and shaded results indicate statistical significance. Abbreviations: PBO, placebo; O-ACY, oral acyclovir; IV-ACY, intravenous acyclovir.

The comparison-adjusted funnel plot for the incidence of HSV by drug class (Figure 8) was asymmetrical, suggesting that the results might be influenced by the sample size of the literature and publication bias.

Based on the comparison-adjusted plots for different dosage forms and total daily doses (Figure 9), no substantial evidence of a small study effect was observed for any outcomes.
Figure 8. Comparison-adjusted funnel plot for incidence of HSV by drug class. Abbreviations: A = acyclovir; B = placebo; C = valacyclovir.

Figure 9. Comparison-adjusted funnel plot for incidence of HSV for different dosage forms and total daily doses. Abbreviations: A, IV acyclovir 10 mg/kg; B, IV acyclovir 250 mg/m²; c, IV acyclovir 500 mg/m²; D, IV acyclovir 750 mg/m²; E, oral acyclovir 1600 mg per day; F, oral acyclovir 2000 mg per day; G, oral acyclovir 800 mg per day; H, placebo.
3.3. Quality of Evidence

The detailed information on the GRADE summary of direct, indirect and NMA evidence for the prevention of oral HSV infection in patients undergoing cancer treatment are presented in Tables 8 and 9, respectively. GRADE evidence of NMA for the efficacy outcome in the primary and subgroup analysis was rated from moderate to high.

Table 8. GRADE summary evidence for primary analysis on prevention of oral HSV infection. Abbreviation: *, Risk of bias; §, Severe imprecision; ‡‡, Indirectness or intransitivity; ¶, Contributing direct evidence of moderate quality.

| Comparison     | Direct Evidence | Indirect Evidence | Network Meta-Analysis |
|----------------|-----------------|-------------------|----------------------|
|                | Odds Ratio (95% Confidence Interval) | Quality of Evidence | Odds Ratio (95% Confidence Interval) | Quality of Evidence | Odds Ratio (95% Confidence Interval) | Quality of Evidence |
| ACY vs. PBO    | 0.18 (0.12, 0.28) | Moderate *‡‡       | 0.17 (0.13, 0.24)    | Moderate ¶, ‡‡     | 0.17 (0.10, 0.30)                 | Moderate               |
| ACY vs. VAL    | 0.79 (0.27, 2.27) | Moderate *         | 0.79 (0.01, 608.3)   | Low ‡‡∥∥§          | 0.79 (0.25, 2.48)                 | Moderate               |

Table 9. GRADE summary evidence for the subgroup analysis (comparison of total daily dose of acyclovir and dosage forms in the prevention of oral HSV incidence). There is no triangle loop formed. Hence, it is impossible to have indirect evidence. Abbreviation: *, Risk of bias; †, imprecision; ‡‡, Indirectness or intransitivity; ‡‡‡, Cannot be estimated because the drug was not connected in a loop in the evidence network.

| Comparison     | Direct Evidence | Indirect Evidence | Network Meta-Analysis |
|----------------|-----------------|-------------------|----------------------|
|                | Odds Ratio (95% Confidence Interval) | Quality of Evidence | Odds Ratio (95% Confidence Interval) | Quality of Evidence | Odds Ratio (95% Confidence Interval) | Quality of Evidence |
| IV-ACY 10MG/KG vs. PBO | 0.14 (0.09, 0.37) | High *            | Not estimable ‡‡       | Not estimable ‡‡     | 0.14 (0.05, 0.37)                 | High                  |
| IV-ACY 200MG/KG2 vs. PBO | 0.41 (0.17, 1.02) | Moderate *‡       | Not estimable ‡‡       | Not estimable ‡‡     | 0.41 (0.17, 1.02)                 | Moderate              |
| IV-ACY 500MG/KG2 vs. PBO | 0.22 (0.03, 1.73) | Moderate *‡       | Not estimable ‡‡       | Not estimable ‡‡     | 0.22 (0.03, 1.73)                 | Moderate              |
| IV-ACY 750MG/KG2 vs. PBO | 0.06 (0.01, 0.39) | High              | Not estimable ‡‡       | Not estimable ‡‡     | 0.06 (0.01, 0.39)                 | High                  |
| O-ACY 1600 vs. PBO    | 0.06 (0.01, 0.45) | Moderate *‡‡       | Not estimable ‡‡       | Not estimable ‡‡     | 0.06 (0.01, 0.45)                 | Moderate              |
| O-ACY 2000 vs. PBO    | 0.18 (0.06, 0.55) | High *            | Not estimable ‡‡       | Not estimable ‡‡     | 0.18 (0.06, 0.55)                 | High                  |
| O-ACY 800 vs. PBO     | 0.05 (0.01, 0.22) | Moderate *‡‡       | Not estimable ‡‡       | Not estimable ‡‡     | 0.07 (0.02, 0.22)                 | Moderate              |

3.4. Prevention of Oral HSV Infection Using Valacyclovir

Due to the limited number of trials evaluating different valacyclovir doses in the prevention of oral HSV infection in patients treated for cancer, a network meta-analysis could not be performed. There were only three RCTs evaluating the efficacy of valacyclovir with the total daily doses ranging from 500 to 2000 mg in preventing oral HSV infection [54–56]. Based on the results of three RCTs, they indicated that valacyclovir was effective in preventing this oral infection among cancer patients as there is no incidence of HSV infection in the valacyclovir-treated group.

3.5. Treatment of Oral HSV Infection

Due to the small number of studies assessing the activity of antiviral agents in the treatment of oral HSV in patient being treated for cancer, NMA could not be performed.

3.6. Secondary Outcomes

NMA was not performed for the secondary outcomes due to the limited number of studies.

4. Discussion

Defining appropriate therapeutic strategies for secondary infections in cancer is challenging due to the multiple levels of immunodeficiency experienced by the patients. Prevention has always remained one of the important strategies to achieve the aforementioned goal.
Using data from randomized control trials, a network meta-analysis was performed comparing the efficacy of antiviral agents in the prevention and treatment of oral HSV infection in patients treated for cancer. To our knowledge, this is the first network meta-analysis that has ranked antiviral agents according to their activity as protective agents against oral HSV infection recurrence, as well as ranking the effectiveness of different acyclovir regimens in the prevention of oral HSV for patients receiving cancer treatment.

Specifically, the results of our network meta-analysis suggest that acyclovir can significantly reduce the relative risk of developing oral HSV infection in patients undergoing cancer treatment. Similarly, valacyclovir shows a significant decrease in the incidence of oral HSV infection in patients undergoing cancer therapy. Our analysis included 16 different RCTs and, according to GRADE, the overall quality of evidence for the network meta-analysis was moderate. Ranking of interventions is one of the most appealing elements of the network meta-analysis. Our network meta-analysis suggests that, in comparison with acyclovir and valacyclovir, acyclovir ranks highest for reducing oral HSV infection incidents in patients being treated for cancer. The visual appearance of the comparison-adjusted funnel plot was asymmetrical, which suggests the existence of publication bias. With respect to the pairwise meta-analysis, the overall pooled relative risk of the acyclovir arm was significantly low, whereas the valacyclovir result was statistically insignificant.

Thirteen RCTs assessing different acyclovir regimens were used to compare the effectiveness of different acyclovir regimens in the prevention of oral HSV infection in patients undergoing cancer treatment. Acyclovir is prescribed in various dosages in an IV form as well as oral formulation. Our network meta-analysis suggests that among the IV formulations, only 750 mg/m² and 10 mg/kg IV regimens were effective in the prevention of oral HSV infections. On the contrary, a total oral daily dose of acyclovir at 800, 1600 as well 2000 mg was effective in the protection against oral HSV infection recurrence. IV acyclovir (750 mg/m²), oral acyclovir (1600 mg per day) and oral acyclovir (800 mg per day) were the best regimens in terms of oral HSV infection prevention in patients receiving cancer treatment. On the other hand, 250 mg/m² per day IV acyclovir was the least effective against the prevention of oral HSV infection recurrence in the same population. As seen from our network meta-analysis results, since acyclovir at 800 mg per day has an almost similar activity to acyclovir at 1600 mg per day with a SUCRA score of 76 and 77%, respectively, clinicians might consider prescribing acyclovir at 800 mg per day as the first line in children and geriatric populations and especially patients with renal impairment. According to H. Izzedine et al. [59], higher doses and prolonged durations of nephrotoxic drugs such as acyclovir increase the risk of acute kidney injury in cancer patients.

According to GRADE, the overall quality of evidence for the subgroup network meta-analysis was high-moderate. However, publication bias was not observed in a comparison-adjusted funnel plot which highlighted the robustness of the selected studies.

Comparing the results of pairwise and network meta-analyses, the prophylactic activity of acyclovir was similar in both methods; however, the network meta-analysis results indicate that valacyclovir is an effective agent in the prevention of oral HSV reactivation, while the pairwise meta-analysis favored placebo and valacyclovir results were statistically insignificant.

Valacyclovir can be considered as an effective agent in the prevention of oral HSV reactivation, with 66.4% activity score according to the SUCRA ranking. Valacyclovir should be considered as the first line drug in patients with swallowing difficulty as well as patients with a history of poor compliance for acyclovir because of the less frequent dosing of valacyclovir compared to acyclovir [60]. Moreover, valacyclovir also offers a high level of bioavailability for cancer patients whose hospitalization solely for IV treatment is neither necessary nor desirable. This result is supported by studies by Honglund et al. [61] and by D Eisen et al. [62], where they stated that valacyclovir offers a significant advantage for bone marrow transplant patients who have difficulty taking oral drugs. Nonetheless, because of insufficient number of trials, publication bias could be identified; hence these results should be interpreted with caution. A possible explanation might be that RCTs with negative outcomes are not being published; researchers usually submit positive outcomes for publication because these
results are more attractive and more likely to be considered by journals, editors and reviewed by peers. However, publication bias has an escalating and damaging impact on knowledge since it leads to significant overestimation and exaggeration of the intervention value, which will eventually lead to false conclusions that can impact the patients’ quality of life.

Our study built on existing evidence on the protective activity of acyclovir and valacyclovir against oral HSV in patients being treated for cancer. The results from the current meta-analysis can be applied practically as a guide for clinicians to choose the most effective acyclovir regimen for the prevention of oral HSV infection in patients undergoing cancer treatment. To support the findings of this network meta-analysis, we used the GRADE approach to assess the quality of evidence. According to GRADE, the quality of evidence ranged between high and moderate.

There were only two available studies that evaluated the antiviral agent’s activity in terms of oral HSV treatment in patients undergoing cancer therapy. Both studies suggested that acyclovir can significantly reduce the time needed to first reduce pain, complete pain resolution, heal and viral shedding. None of the available trials examined the effectiveness of valacyclovir for the treatment of oral HSV in patients being treated for cancer. Further trials are needed to address the questions of which antiviral agent is the most effective and safer to treat oral HSV infection in patients receiving cancer treatment and what is the optimum dose and dosage form to be used.

Several trials reported adverse effects in the acyclovir arm such as rise in hepatic transaminases Serum glutamic oxaloacetic transaminase (SGOT) and Serum glutamic pyruvic transaminase (SGPT), rash, nephrotoxicity and delirium. Similar adverse effects were reported in the placebo arm, suggesting that acyclovir is not the primary cause of these adverse effects. With respect to the elevated liver enzymes, the likelihood of acyclovir being the causative agent is very low (score D—possible rare cause of clinically apparent liver injury) and, if so, it is considered to be asymptomatic and self-limited. Liver toxicity could also be due to herpes simplex infection as hepatotoxicity and jaundice has been reported with HSV infection [63]. Moreover, it could be induced by cancer cytotoxic treatment as well [64]. There are many reasons attributed to acyclovir nephrotoxicity—for example, acyclovir is considered relatively insoluble in urine; however, approximately 60–90% of acyclovir will be excreted unchanged by the kidney which may lead to crystal-induced nephropathy. The clinical manifestations of crystal-induced nephropathy are renal function deterioration and rapid elevation of serum creatinine within the first two days of acyclovir administration [65,66]. Adair et al. [67], reported thirty cases of nephrotoxicity associated with acyclovir in patients who were devoid of renal disease prior to acyclovir administration. Thus, in order to avoid or reduce the risk of nephrotoxicity, IV acyclovir is recommended to be infused over 1 h to prevent high acyclovir concentrations accompanied by patient hydration before and during therapy [68]. In patients with deteriorated kidney function, lower doses and longer dosing intervals might be required [65].

Likewise, National Comprehensive Cancer Network (NCCN) guidelines recommend prophylactic administration of acyclovir, famciclovir or valacyclovir against oral HSV in seropositive patients who receive chemotherapy throughout the period of neutropenia for acute leukemia and for allogeneic and autologous Haematopoietic Stem Cell transplantation (HSCT), patients [69,70]. However, the recommendations have not specified the dosage recommendations. Other guideline also suggested acyclovir and valacyclovir as a grade A recommendation with level of evidence I according to the hierarchy of evidence [71]. The Infectious Diseases Working Party (AGIHO) of the German Society for Hematology and Medical Oncology (DGHO) recommended giving 400 mg oral acyclovir three or four times per day or valacyclovir 500 mg orally twice or thrice daily as prophylaxis against oral HSV [25]. The current network meta-analysis is with an agreement with all mentioned guidelines; moreover the results from this network meta-analysis results highlight the dosages which are the most effective in terms of HSV-1 prevention in patients receiving cancer treatment.

Previously, a pairwise meta-analysis by Glenny et al. [72] indicated the effectiveness of acyclovir as an intervention for the prevention and treatment of oral HSV infection. Yahav et al. [73] conducted pairwise meta-analyses to assess the antiviral prophylaxis activity against oral HSV infection and
cytomegalovirus (CMV) in patients undergoing hematopoietic stem cell transplantation or intensive chemotherapy for acute leukemia or high-grade lymphoma.

HSV reactivation is very common in patients suffering from hematological malignancies and account for 37 and 68% of all oral lesions in all cancer patients [74]. The meta-analysis suggested that in the pre-engraftment setting of autologous or allogeneic (HSCT), acyclovir can significantly reduce the incidence of oral HSV infection and CMV, with no effect on overall mortality. On the other hand, in the allogeneic post-engraftment setting, acyclovir showed a significant reduction in the overall mortality, while in patients receiving chemotherapy, acyclovir showed a substantial effect in reducing oral HSV infection incidence but had no effect on mortality. Both these meta-analyses support our finding that acyclovir is an effective antiviral agent in the prevention of oral HSV infection in patients being treated for cancer.

Although conventional meta-analyses can provide a high-precision effect estimate, it addresses only one pair of comparisons, usually one intervention and placebo; consequently, it is not considered highly beneficial in case of the presence of multiple alternative interventions [75,76]. Network meta-analysis is known as a technique for comparing three or more interventions simultaneously in a single analysis by combining both direct and indirect evidence across a network of studies. Network meta-analysis provides more precise estimates than a single direct or indirect estimate [76]. By using network meta-analysis, we were able to compare the preventive activity of valacyclovir, acyclovir and placebo against oral HSV infection. Moreover, we also compared the preventive activity of different acyclovir regimens against oral HSV infection. Previous pairwise meta-analysis did not provide intervention ranking according to its effectiveness; however, we used a SUCRA curve to present an overall ranking to rank the best antiviral agent for the prevention of oral HSV infection in the first analysis, as well as the best acyclovir dose regimens in the prevention of oral HSV infection in patients being treated for cancer. Additionally, to assess the degree of confidence or certainty of our findings, we used the GRADE approach, which is the most recommended approach for the evolution of strength of evidence [77].

The current study has several limitations. Firstly, the timing of initiation of treatment was different among different trials. For instance, in the trial conducted by Saral et al. [20], 250 mg/m² IV acyclovir was given either for 32 days or until the patients were discharged from the hospital or until a positive culture of herpes simplex virus infection was found. In Lundgren et al.’s study [47], 250 mg/m² IV acyclovir administered twice daily was given five days before transplantation and stopped at the fifth week after transplantation. The antiviral agents’ effectiveness might be affected by these differences between protocols and may lead to analysis bias. Secondly, the included patients in different trials would have been exposed to various triggers such as sunlight and dental treatment which could have possibly triggered HSV activation. Moreover, patients had different neoplasm types and received different anticancer regimens which might influenced on HSV 1 activation, hence leading to analysis bias. The differences in genetic makeup and demographic characteristics of the subjects, trial conducts and methodology across studies can also generate considerable heterogeneity. Since only 23% of the assessed trials had an adequate allocation concealment, future studies should take into account the importance of allocation concealment in preventing selection bias and its impact on overall study results; moreover, several aspects should be encouraged in future studies such as using sensitive methods to detect oral HSV reactivation, more focused study designs and most recent protocols.

The question of which valacyclovir regimen is the most effective and safer to prevent oral HSV infection in patients receiving cancer treatment has remained controversial due to the limited number of studies, as NMA could not be performed. Encouraging RCTs to assess valacyclovir activity in the prevention of oral HSV in patients undergoing cancer treatment is highly recommended. Valacyclovir is considered more cost-effective when compared to acyclovir because valacyclovir requires less-frequent dosing and hence higher patient compliance. Dignani et al. [78] assessed the cost of prophylactic valacyclovir compared to IV acyclovir in autologous progenitor cell transplantation patients; prophylactic valacyclovir could save up to USD 60,600 for autologous progenitor cell transplantation patients.
A significant finding from our literature review is that the majority of trials examined oral HSV infection reactivation in hematological malignancies such as leukemia, myeloma and lymphoma. In contrast, few trials assessed patients with head and neck cancer and solid tumors, which suggests that patients with hematological malignancies are at a high risk of developing oral HSV infection reactivation [79]. Furthermore, the prevalence of oral HSV infection reactivation is significantly higher in the most recent studies compared to older studies; a possible explanation for this could be the more sensitive laboratory techniques that have been used lately and thereby improved detection.

Overall, our analysis results should provide guidance in choosing the right regimen tailored to an individual patient’s needs.

5. Conclusions

The success of cancer treatment is usually compromised by oral complications, especially HSV reactivation, which plays a part in patients’ quality of life and cancer treatment progression. This research aimed to identify the best antiviral agent to prevent or to treat oral HSV in patients being treated for cancer. Acyclovir and valacyclovir were found to be highly effective in the prevention of HSV-1 in patients being treated for cancer. Acyclovir is superior compared to valacyclovir. The best acyclovir regimens that can be prescribed by healthcare providers in order to prevent oral HSV in patients being treated for cancer are 750 mg/m² IV acyclovir, 1600 mg oral acyclovir as a total daily dose and 800 mg acyclovir per day. The least effective regimen is 250 mg/m² IV acyclovir. The literature review highlighted the lack of RCTs in the area of HSV-1 treatment in patients undergoing cancer treatment, as only a few studies assessed this part; hence the question of which antiviral agent is most effective in treating HSV-1 in patients undergoing cancer treatment has not been answered yet. Further RCTs are encouraged to be carried out assessing this issue. Remarkably, a small number of included articles had adequate allocation concealment; it is highly recommended to emphasize the importance of allocation concealment in reducing the risk of bias if future trials.

Author Contributions: F.W.A.A.-Z. drafted the protocol. R.K.M. and S.K.V. revised the protocol. F.W.A.A.-Z. and L.Y.S. conducted the identification of trials, trial selection and data extraction. F.W.A.A.-Z. and L.Y.S. assessed the risk of bias independently. F.W.A.A.-Z., L.Y.S. and S.K.V. conducted the standard statistical analyses. F.W.A.A.-Z., R.K.M., L.Y.S., M.K.M. and D.G. drafted and revised the review. R.K.M., L.Y.S., D.G. and M.K.M. revised the review. All authors reviewed and commented on the article and approved the final version of the manuscript. All authors have read and agreed to the published version of the manuscript.

Funding: The project has been funded by the Institute for Research, Development and Innovation (IRDI), International Medical University, Kuala Lumpur, Malaysia (Project ID No: MPP I/2020(02)).

Conflicts of Interest: The authors declare no conflict of interest. Authors must identify and declare any personal circumstances or interest that may be perceived as inappropriately influencing the representation or interpretation of reported research results. Any role of the funders in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results must be declared in this section. If there is no role, please state “The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results”.

Appendix A

Table A1. Search terms used in search strategy.

| #   | Keyword                      | Medline (Ovid) | Embase         | Cochrane Central |
|-----|------------------------------|----------------|----------------|-----------------|
| 1   | exp NEOPLASMS/               | 3,327,198      | 4,250,169      | 77,595          |
| 2   | exp LEUKEMIA/                | 231,072        | 281,659        | 4644            |
| 3   | exp LYMPHOMA/                | 170,934        | 278,418        | 3173            |
| 4   | exp RADIOTHERAPY/            | 184,530        | 502,025        | 5856            |
| 5   | Chemotherapy.mp.             | 434,962        | 782,593        | 78,184          |
| 6   | Bone Marrow Transplantation/ | 44,512         | 48,482         | 1368            |
### Table A1. Cont.

| # | Keyword Medline (Ovid) | Embase | Cochrane Central |
|---|-----------------------|--------|------------------|
| 7 | neoplasm$.mp. | 2,803,199 | 756,571 | 79,397 |
| 8 | cancer$.mp. | 1,769,905 | 3,491,963 | 169,046 |
| 9 | (leukaemia$ or leukemi$).mp. | 326,549 | 437,588 | 15,026 |
| 10 | (tumour$ or tumor$).mp. | 2,085,918 | 2,992,357 | 78,405 |
| 11 | malignan$.mp. | 569,105 | 861,406 | 27,680 |
| 12 | neutropeni$.mp. | 44,306 | 128,428 | 14,301 |
| 13 | carcino$.mp. | 1,021,355 | 1,423,938 | 45,899 |
| 14 | adenocarcinoma$.mp. | 238,058 | 269,624 | 11,190 |
| 15 | lymphoma$.mp. | 242,728 | 314,058 | 12,414 |
| 16 | (radioth$ or radiat$ or irradiat$ or radiochemo$).mp. | 893,029 | 1,226,258 | 51,508 |
| 17 | (bone adj marrow adj5 transplant$).mp | 5,8628 | 85,127 | 4001 |
| 18 | chemo$.mp. | 753,479 | 1,307,643 | 92,912 |
| 19 | or/1–18 | 5,244,394 | 6,656,084 | 271,167 |
| 20 | herpes simplex/or herpes labialis/or stomatitis, herpetic/ | 15,890 | 19,232 | 462 |
| 21 | (herpes or herpetic or “cold sore$”or cold-sore$).mp. | 72,420 | 116,809 | 4872 |
| 22 | simplexvirus/or herpesvirus 1, human/ | 27,442 | 3361 | 195 |
| 23 | HSV$.mp. | 25,977 | 32,427 | 862 |
| 24 | fever blister$.mp. | 39 | 53 | 5 |
| 25 | (oral adj3 infection).ti,ab. | 4631 | 5331 | 430 |
| 26 | (oral and vir$).ti,ab. | 27,253 | 36,737 | 4175 |
| 27 | or/20–26 | 106,267 | 157,685 | 9211 |
| 28 | exp Randomized Controlled Trial/ | 508,037 | 603,738 | 131 |
| 29 | exp Clinical Trial/ | 861,035 | 1,486,491 | 163 |
| 30 | randomized controlled trial.pt. | 507,205 | 0 | 495,880 |
| 31 | random$.tw. | 1,113,139 | 1,526,873 | 956,392 |
| 32 | blind$.ti,ab. | 291,995 | 408,397 | 319,311 |
| 33 | placebo$.ti,ab. | 212,210 | 302,942 | 298,344 |
| 34 | trial$.ti,ab. | 1,005,908 | 1,432,033 | 652,484 |
| 35 | or/28–34 | 2,163,766 | 3,165,315 | 1,236,237 |
| 36 | exp Acyclovir/ | 14,207 | 38,744 | 1205 |
| 37 | exp Zovirax/ | 14,207 | 38,744 | 1205 |
| 38 | antiviral$.ti,ab. | 85,534 | 115,959 | 5684 |
| 39 | exp Valacyclovir/ | 1060 | 7794 | - |
| 40 | exp Valtrex/ | 1060 | 7794 | - |
| 41 | exp Famciclovir/ | 529 | 3865 | - |
| 42 | exp Famvir/ | 529 | 3865 | - |
| 43 | anti viral$.ti,ab. | 6856 | 11,216 | 448 |
| 44 | antitherpetic.mp. | 519 | 638 | 16 |
| 45 | exp Acycloguanosine/ | 14,207 | 38,744 | 1205 |
| 46 | or/36–45 | 102,879 | 161,355 | 7036 |
| 47 | 19 AND 27 AND 35 AND 46 | 599 | 1863 | 197 |
| 48 | limit 47 to humans limit 47 to (english language and humans) | 484 | 1680 | 151 |
21. Ci, B.; Jc, W. Herpes simplex virus infection in the immunocompromised cancer patient. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 1991, 9, 1903–1915. [CrossRef]
22. Saral, R.; Burns, W.H.; Prentice, H.G. Herpes virus infections: Clinical manifestations and therapeutic strategies in immunocompromised patients. Clin. Haematol. 1984, 13, 645–660. [PubMed]
23. Lam, M.T.; Pazin, G.J.; Armstrong, J.A.; Ho, M. Herpes simplex infection in acute myelogenous leukemia and other hematologic malignancies: A prospective study. Cancer 1981, 48, 2168–2171. [CrossRef]
24. Styczynski, J.; Reussier, P.; Einsele, H.; de la Camara, R.; Cordonnier, C.; Ward, K.N.; Ljungman, P.; Engelhard, D. Management of HSV, VZV and EBV infections in patients with hematological malignancies and after SCT: Guidelines from the Second Conference on Infections in Leukemia. Bone Marrow Transplant. 2009, 43, 757–770. [CrossRef] [PubMed]
25. Sandherr, M.; Einsele, H.; Hebart, H.; Kahl, C.; Kern, W.; Kiehl, M.; Massenkeil, G.; Penack, O.; Schiel, X.; Schuettrumpf, S.; et al. Antiviral prophylaxis in patients with haematological malignancies and solid tumours: Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society for Hematology and Oncology (DGHO). Ann. Oncol. Off. J. Eur. Soc. Med. Oncol. 2006, 17, 1051–1059. [CrossRef] [PubMed]
26. Ljungman, P. Risk assessment in haematopoietic stem cell transplantation: Viral status. Best Pract. Res. Clin. Haematol. 2007, 20, 209–217. [CrossRef]
27. Centers for Disease Control and Prevention; Infectious Disease Society of America; American Society of Blood and Marrow Transplantation. Guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients. MMWR Recomm. Rep. 2000, 49, 1–125.
28. Opstelten, W.; Neven, A.K.; Eekhof, J. Treatment and prevention of herpes labialis. Can. Fam. Physician 2008, 54, 1683–1687.
29. Kimberlin, D.W.; Whitley, R.J. Antiviral therapy of HSV-1 and -2. In Human Herpesviruses: Biology, Therapy, and Immunoprophylaxis; Arvin, A., Campadelli-Fiume, G., Mocarski, E., Moore, P.S., Roizman, B., Whitley, R., Yamanishi, K., Eds.; Cambridge University Press: Cambridge, UK, 2007; ISBN 978-0-521-82714-0.
30. Laskin, O.L. Clinical Pharmacokinetics of Acyclovir. Clin. Pharmacokinet. 1983, 8, 187–201. [CrossRef] [PubMed]
31. Cernik, C.; Gallina, K.; Brodell, R.T. The treatment of herpes simplex infections: An evidence-based review. Arch. Intern. Med. 2008, 168, 1137–1144. [CrossRef] [PubMed]
32. Higgins, J.P.; Green, S. Cochrane Handbook for Systematic Reviews of Interventions: Cochrane Book Series; John and Wiley and Sons: Hoboken, NJ, USA, 2008; p. 674.
33. Hutton, B.; Salanti, G.; Caldwell, D.M.; Chaimani, A.; Schmid, C.H.; Cameron, C.; Ioannidis, J.P.A.; Straus, S.; Thorlund, K.; Jansen, J.P.; et al. The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: Checklist and explanations. Ann. Intern. Med. 2015, 162, 777–784. [CrossRef]
34. McCoy, C.E. Understanding the Intention-to-treat Principle in Randomized Controlled Trials. West. J. Emerg. Med. 2017, 18, 1075–1078. [CrossRef] [PubMed]
35. Sterne, J.A.C.; Savovic, J.; Page, M.J.; Elbers, R.G.; Blencowe, N.S.; Boutron, I.; Cates, C.J.; Cheng, H.-Y.; Corbett, M.S.; Eldridge, S.M.; et al. RoB 2: A revised tool for assessing risk of bias in randomised trials. BMJ 2019, 366. [CrossRef] [PubMed]
36. Simultaneous Comparison of Multiple Treatments: Combining Direct and Indirect Evidence—PubMed. Available online: https://pubmed.ncbi.nlm.nih.gov/16223826/ (accessed on 27 July 2020).
37. Hoaglin, D.C.; Hawkins, N.; Jansen, J.P.; Scott, D.A.; Itzler, R.; Cappelleri, J.C.; Boersma, C.; Thompson, D.; Lahrholt, K.M.; Diaz, M.; et al. Conducting indirect-treatment-comparison and network-meta-analysis studies: Report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: Part 2. Value Health J. Int. Soc. Pharm. Outcomes Res. 2011, 14, 429–437. [CrossRef] [PubMed]
38. Gluckman, E.; Lotsberg, J.; Deveerg, A.; Zhao, X.M.; Melo, R.; Gomez-Morales, M.; Mazeron, M.C.; Perol, Y. Oral acyclovir prophylactic treatment of herpes simplex infection after bone marrow transplantation. J. Antimicrob. Chemother. 1983, 12, 161–167. [CrossRef] [PubMed]
39. Bergmann, O.J.; Ellermann-Eriksen, S.; Mogensen, S.C.; Ellegaard, J. Acyclovir given as prophylaxis against oral ulcers in acute myeloid leukaemia: Randomised, double blind, placebo controlled trial. BMJ 1995, 310, 1169–1172. [CrossRef] [PubMed]
40. Prentice, H.G.; Hann, I.M. Prophylactic studies against herpes infections in severely immunocompromised patients with acyclovir. J. Infect. 1983, 6, 17–21. [CrossRef]
41. Laskin, O.L.; Saral, R.; Burns, W.H.; Angelopoulos, C.M.; Lietman, P.S. Acyclovir concentrations and tolerance during repetitive administration for 18 days. *Am. J. Med.* 1982, 73, 221–224. [CrossRef]

42. Gluckman, E.; Devergie, A.; Melo, R.; Nebout, T.; Løtsberg, J.; Zhao, X.M.; Gomez-Morales, M.; Mazeron, M.C.; Perol, Y. Prophylaxis of herpes infections after bone-marrow transplantation by oral acyclovir. *Lancet* 1983, 322, 706–708. [CrossRef]

43. Hann, I.M.; Prentice, H.G.; Blacklock, H.A.; Ross, M.G.; Brigden, D.; Rosling, A.E.; Burke, C.; Crawford, D.H.; Brumfitt, W.; Hoffbrand, A.V. Acyclovir prophylaxis against herpes virus infections in severely immunocompromised patients: Randomised double blind trial. *Br. Med. J. Clin. Res. Ed.* 1983, 287, 384–388. [CrossRef] [PubMed]

44. Prentice, H.G. Use of acyclovir for prophylaxis of herpes infections in severely immunocompromised patients. *J. Antimicrob. Chemother.* 1983, 12, 153–159. [CrossRef] [PubMed]

45. Anderson, H.; Scarfe, J.H.; Sutton, R.N.; Hickmott, E.; Brigden, D.; Burke, C. Oral acyclovir prophylaxis against herpes simplex virus in non-Hodgkin lymphoma and acute lymphoblastic leukaemia patients receiving remission induction chemotherapy. A randomised double blind, placebo controlled trial. *Br. J. Cancer* 1984, 50, 45–49. [CrossRef] [PubMed]

46. Wade, J.C.; Newton, B.; Flournoy, N.; Meyers, J.D. Oral Acyclovir for Prevention of Herpes Simplex Virus Reactivation after Marrow Transplantation. *Ann. Intern. Med.* 1984, 100, 823–828. [CrossRef] [PubMed]

47. Lundgren, G.; Wilczek, H.; Lönnqvist, B.; Lindholm, A.; Wahren, B.; Ringdén, O. Acyclovir prophylaxis in bone marrow transplant recipients. * scand. j. Infect. Dis. Suppl.* 1985, 47, 137–144. [PubMed]

48. Shepp, D.H.; Dandliker, P.S.; Flournoy, N.; Meyers, J.D. Once-daily intravenous acyclovir for prophylaxis of herpes simplex virus reactivation after marrow transplantation. *J. Antimicrob. Chemother.* 1985, 16, 389–395. [CrossRef] [PubMed]

49. Shepp, D.H.; Dandliker, P.S.; Flournoy, N.; Meyers, J.D. Sequential intravenous and twice-daily oral acyclovir for extended prophylaxis of herpes simplex virus infection in marrow transplant patients. *Transplantation* 1987, 43, 654–658. [CrossRef] [PubMed]

50. Bubley, G.J.; Chapman, B.; Chapman, S.K.; Crumpacker, C.S.; Schnipper, L.E. Effect of acyclovir on radiation- and chemotherapy-induced mouth lesions. *Antimicrob. Agents Chemother.* 1989, 33, 862–865. [CrossRef] [PubMed]

51. Selby, P.J.; Powlès, R.L.; Easton, D.; Perren, T.J.; Stolle, K.; Jameson, B.; Fiddian, A.P.; Tryhorn, Y.; Stern, H. The prophylactic role of intravenous and long-term oral acyclovir after allogeneic bone marrow transplantation. *Br. J. Cancer* 1989, 59, 434–438. [CrossRef]

52. Lönnqvist, B.; Palmblad, J.; Ljungman, P.; Grimfors, G.; Järnmark, M.; Lerner, R.; Nyström-Rosander, C.; Öberg, G. The Leukemia Group of Middle Sweden Oral acyclovir as prophylaxis for bacterial infections during induction therapy for acute leukaemia in adults. *Support. Care Cancer* 1993, 1, 139–144. [CrossRef]

53. Bergmann, O.J.; Mogensen, S.C.; Ellermann-Eriksen, S.; Elleegaard, J. Acyclovir prophylaxis and fever during remission-induction therapy of patients with acute myeloid leukemia: A randomized, double-blind, placebo-controlled trial. *J. Clin. Oncol.* 1997, 15, 2269–2274. [CrossRef]

54. Liesveld, J.L.; Abboud, C.N.; Iffihkaruddin, J.J.; Lancet, J.E.; Wedow, L.A.; Oliva, J.; Stamm, C.G.; Nichols, D. Oral valacyclovir versus intravenous acyclovir in preventing herpes simplex virus infections in autologous stem cell transplant recipients. *Biol. Blood Marrow Transplant.* 2002, 8, 662–665. [CrossRef]

55. Warkentin, D.I.; Epstein, J.B.; Campbell, L.M.; Yip, J.G.; Cox, V.C.; Ransier, A.; Barnett, M.J.; Marra, F. Valacyclovir versus acyclovir for HSV prophylaxis in neutropenic patients. *Ann. Pharmacother.* 2002, 36, 1525–1531. [CrossRef] [PubMed]

56. Orłowski, R.; Mills, S.; Hartley, E.; Ye, X.; Piantadosi, S.; Ambinder, R.; Gore, S.; Miller, C. Oral Valacyclovir as Prophylaxis against Herpes Simplex Virus Reactivation During High Dose Chemotherapy for Leukemia. *Leuk. Lymphoma* 2004, 45, 2215–2219. [CrossRef] [PubMed]

57. Wade, J.C.; Newton, B.; McLAREN, C.; Flournoy, N.; Keeney, R.E.; Meyers, J.D. Intravenous Ayclovir to Treat Mucocutaneous Herpes Simplex Virus Infection After Marrow Transplantation. *Ann. Intern. Med.* 1982, 96, 265–269. [CrossRef] [PubMed]

58. Shepp, D.H.; Newton, B.A.; Dandliker, P.S.; Flournoy, N.; Meyers, J.D. Oral acyclovir therapy for mucocutaneous herpes simplex virus infections in immunocompromised marrow transplant recipients. *Ann. Intern. Med.* 1985, 102, 783–785. [CrossRef] [PubMed]

59. Izzedine, H.; Perazella, M.A. Anticancer Drug-Induced Acute Kidney Injury. *Kidney Int. Rep.* 2017, 2, 504–514. [CrossRef] [PubMed]
60. Zeng, L.; Nath, C.E.; Blair, E.Y.L.; Shaw, P.J.; Stephen, K.; Earl, J.W.; Coakley, J.C.; McLachlan, A.J. Population Pharmacokinetics of Acyclovir in Children and Young People with Malignancy after Administration of Intravenous Acyclovir or Oral Valacyclovir. Antimicrob. Agents Chemother. 2009, 53, 2918–2927. [CrossRef] [PubMed]

61. Höglund, M.; Ljungman, P.; Weller, S. Comparable aciclovir exposures produced by oral valaciclovir and intravenous aciclovir in immunocompromised cancer patients. J. Antimicrob. Chemother. 2001, 47, 855–861. [CrossRef]

62. Eisen, D.; Essell, J.; Broun, E.; Sigmund, D.; DeVoe, M. Clinical Utility of Oral Valacyclovir Compared with Oral Acyclovir for the Prevention of Herpes Simplex Virus Mucositis Following Autologous Bone Marrow Transplantation or Stem Cell Rescue Therapy. Available online: https://pubmed.ncbi.nlm.nih.gov/12621507/ (accessed on 28 July 2020).

63. Talwani, R.; Gilliam, B.L.; Howell, C. Infectious Diseases and the Liver. Clin. Liver Dis. 2011, 15, 111–130. [CrossRef]

64. Acyclovir. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury; National Institute of Diabetes and Digestive and Kidney Diseases: Bethesda, MD, USA, 2012.

65. Yildiz, C.; Ozsurekci, Y.; Gucer, S.; Cengiz, A.B.; Topaloglu, R. Acute kidney injury due to acyclovir. CEN Case Rep. 2012, 2, 38–40. [CrossRef]

66. Fleischer, R.; Johnson, M. Acyclovir Nephrotoxicity: A Case Report Highlighting the Importance of Prevention, Detection, and Treatment of Acyclovir-Induced Nephropathy. Case Rep. Med. 2010. [CrossRef]

67. Adair, J.C.; Gold, M.; Bond, R.E. Acyclovir neurotoxicity: Clinical experience and review of the literature. South Med. J. 1994, 87, 1227–1231. [CrossRef] [PubMed]

68. Dubrofsky, L.; Kerzner, R.S.; Delaunay, C.; Kolenda, C.; Pepin, J.; Schwartz, B.C. Interdisciplinary Systems-Based Intervention to Improve IV Hydration during Parenteral Administration of Acyclovir. Can. J. Hosp. Pharm. 2016, 69, 7–13. [CrossRef]

69. Baden, L.R.; Swaminathan, S.; Angarone, M.; Blouin, G.; Camins, B.C.; Casper, C.; Cooper, B.; Dubberke, E.R.; Engemann, A.M.; Freifeld, A.G.; et al. Prevention and Treatment of Cancer-Related Infections, Version 2.2016, NCCN Clinical Practice Guidelines in Oncology. J. Natl. Compr. Cancer Netw. JNCCN 2016, 14, 882–913. [CrossRef] [PubMed]

70. Hadorn, D.C.; Baker, D.; Hodges, J.S.; Hicks, N. Rating the quality of evidence for clinical practice guidelines. J. Clin. Epidemiol. 1996, 49, 749–754. [CrossRef]

71. Lalla, R.V.; Bowen, J.; Barasch, A.; Elting, L.; Keefe, D.M.; McGuire, D.B.; Migliorati, C.; Nicolatou-Galitis, O.; Peterson, D.E.; et al. MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy: MASCC/ISOO Mucositis Guidelines. Cancer 2014, 120, 1453–1461. [CrossRef]

72. Glenny, A.-M.; Fernandez Maulefich, L.M.; Pavitt, S.; Walsh, T. Interventions for the prevention and treatment of herpes simplex virus in patients being treated for cancer. Cochrane Database Syst. Rev. 2009, CD006706. [CrossRef] [PubMed]

73. Yahav, D.; Gafter-Gvili, A.; Muchtar, E.; Skalsky, K.; Kariv, G.; Yeshurun, M.; Leibovici, L.; Paul, M. Antiviral prophylaxis in haematological patients: Systematic review and meta-analysis. Eur. J. Cancer Oxf. Engl. 1990 2009, 45, 3131–3148. [CrossRef]

74. Djuric, M.; Jankovic, L.; Jovanovic, T.; Pavlica, D.; Brkic, S.; Knezevic, A.; Markovic, D.; Milasin, J. Prevalence of oral herpes simplex virus reactivation in cancer patients: A comparison of different techniques of viral detection. J. Oral Pathol. Med. Off. Publ. Int. Assoc. Oral Pathol. Am. Acad. Oral Pathol. 2009, 38, 167–173. [CrossRef]

75. Gopalakrishnan, S.; Ganeshkumar, P. Systematic Reviews and Meta-analysis: Understanding the Best Evidence in Primary Healthcare. J. Fam. Med. Prim. Care 2013, 2, 9–14. [CrossRef]

76. Zafari, Z.; Thorlund, K.; FitzGerald, J.M.; Marra, C.A.; Sadatsafavi, M. Network vs. pairwise meta-analyses: A case study of the impact of an evidence-synthesis paradigm on value of information outcomes. Pharmacoeconomics 2014, 32, 995–1004. [CrossRef]

77. Puhan, M.A.; Schünemann, H.J.; Murad, M.H.; Li, T.; Brignardello-Petersen, R.; Singh, J.A.; Kessels, A.G.; Guyatt, G.H. GRADE Working Group A GRADE Working Group approach for rating the quality of treatment effect estimates from network meta-analysis. BMJ 2014, 349, g6530. [CrossRef] [PubMed]
78. Dignani, M.C.; Mykietiuk, A.; Michelet, M.; Intile, D.; Mammana, L.; Desmery, P.; Milone, G.; Pavlovsky, S. Valacyclovir prophylaxis for the prevention of Herpes simplex virus reactivation in recipients of progenitor cells transplantation. *Bone Marrow Transplant.* 2002, 29, 263–267. [CrossRef] [PubMed]

79. Hong, J.; Park, H.-K.; Park, S.; Lee, A.; Lee, Y.-H.; Shin, D.-Y.; Koh, Y.; Choi, J.-Y.; Yoon, S.-S.; Choi, Y.; et al. Strong association between herpes simplex virus-1 and chemotherapy-induced oral mucositis in patients with hematologic malignancies. *Korean J. Intern. Med.* 2020, 35, 1188–1198. [CrossRef] [PubMed]

**Publisher’s Note:** MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).